Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Eisai’s Insomnia Drug Grabs US Approval, Japan Nod Expected Soon
December 24, 2019
- US FDA Accepts Resubmission for Sunovion’s Parkinson’s Med
December 24, 2019
- Promethera to Launch Japan Trial of Cell Therapy Targeting ACLF by FY2021
December 24, 2019
- FDA Nixes Takeda’s Subcutaneous Entyvio Formulation
December 24, 2019
- Daiichi Sankyo, AZ Nab US Nod for ADC Enhertu in Breast Cancer
December 24, 2019
- Sumitomo/Poxel Wraps Up Japan Pivotal Program for Imeglimin with Successful Long-Term Study
December 23, 2019
- Bayer, Santen Extend Eylea Tie-Up in Japan
December 23, 2019
- Daiichi Sankyo/Amgen’s Avastin Biosimilar Now Available
December 20, 2019
- Astellas/Seattle Genetics Nabs FDA OK for 1st-in-Class ADC
December 20, 2019
- Takahiko Iwaya to Take Over as Sanofi Japan President on Jan. 1
December 20, 2019
- Takecab Back on Top in Hospital Promotion Ranking in October: Impact Track
December 19, 2019
- Biogen Eyes 2020 Aducanumab Filing in Japan Too, Nailing Down Re-Dosing Study Details
December 19, 2019
- Jardiance Delivers Favorable Data in Asian RWD Analysis: Boehringer/Lilly
December 19, 2019
- Daiichi Sankyo Aims to Become Global Leader of ADCs: CEO
December 18, 2019
- Chugai Names EVP Okuda as New President
December 18, 2019
- Xtandi Bags Label Expansion in US for Metastatic Castration-Sensitive Prostate Cancer: Astellas/Pfizer
December 18, 2019
- Meiji Pharma Begins PI for Stelara Biosimilar in Europe
December 17, 2019
- Astellas Launches Tender Offer for Audentes
December 17, 2019
- Rohto to Initiate Japan PI of JAK Inhibitor in Ophthalmology Field Later This Month
December 17, 2019
- Sumitomo Dainippon Pulls Plug on SanBio’s Lead Cell Therapy
December 16, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…